PRESS RELEASES

Date Title and Summary View
Toggle Summary Glycomimetics Announces Publication in Nature Medicine of Preclinical Data for its GMI-1070 Drug Candidate
– Antagonizing E-selectin, a primary function of GMI-1070, can protect hematopoietic stem cells from toxicity of chemotherapy –
View HTML
Toggle Summary GlycoMimetics, Inc. Announces Presentation at National Sickle Cell Conference
GlycoMimetics, Inc. Announces Presentation at National Sickle Cell Conference GAITHERSBURG, MD, September 24, 2012 – GlycoMimetics, Inc. a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that they
View HTML
Toggle Summary William E. Proudford Sickle Cell Fund Honors GlycoMimetics, Inc. With “Unsung Hero” Award
— Biotechnology company honored for work in development of clinical drug candidate for the potential treatment of vaso-occlusive crisis of sickle cell disease. —
View HTML
Toggle Summary Tech Council of Maryland Names GlycoMimetics as 2012 Life Sciences Company of the Year
Tech Council of Maryland Names GlycoMimetics as 2012 Life Sciences Company of the Year GAITHERSBURG, Md., April 27, 2012 – GlycoMimetics, Inc. a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that
View HTML
Toggle Summary IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate
IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate NEW YORK, NY, GAITHERSBURG, MD, and ATHENS, GA, May 9, 2012 – The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC
View HTML
Toggle Summary GlycoMimetics Announces Two Key Leadership Promotions
— Helen Thackray, M.D., Appointed Chief Medical Officer; Brian Hahn Named Chief Financial Officer —
View HTML
Toggle Summary Progress of GlycoMimetics' Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology View HTML
Toggle Summary GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease View HTML
Toggle Summary GlycoMimetics Announces Data Presentations on Lead Compound at American Society of Hematology Annual Meeting View HTML
Toggle Summary Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model View HTML